Topic of Study: Breast Cancer This is a Phase III, Double-blind, Randomized study to assess switching to AZD9833 (a Next Generation, Oral SERD) plus a CDK4/6 Inhibitor (Palbociclib or Abemaciclib) versus continuing an Aromatase Inhibitor (Letrozole or Anastrozole) plus CDK4/6 Inhibitor in patients with Hormone receptor positive (HR+), HER2 negative metastatic breast cancer with a detectable ESR1 Mutation without disease progression during first line treatment. - A ctDNA Guided Early Switch Study (Clinicaltrials.gov ID#: NCT04964934) 

Topic of Study: Breast Cancer This study is a randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for first line, metastatic HER+2 breast cancer (Clinicaltrials.gov ID#: NCT05132582).  

Topic of Study: Other This study involves storing specimens from CRS/HIPEC patients with advanced colorectal, gastric, small bowel, primary peritoneal, ovarian cancers, peritoneal mesothelioma, and sarcomas. The purpose is to collect, maintain, and store tissues specimens from CRS/HIPEC and clinical data for future research. The collection of clinical data and outcomes from CRS/HIPEC for advanced intra-abdominal cancers will be used to refine future treatment protocols and enhance patient care

Mercy primary care physician Dr. Shannarose Guma discusses essentials you should have for you and your family.

Mercy joint replacement surgeon Dr. Joseph Ciotola discusses when you should consider joint replacement surgery.

Dr. Zheng and Ms. Henning discuss their roles at the Neurology Center at Mercy.

Mercy's Dr. Ayesha Cheema discusses questions you should ask a primary care physician.

Mercy plastic surgeon Dr. Lauren Nigro discusses breast reconstruction after lumpectomy.

Sister Helen Amos, RSM, Mercy Board of Trustees Executive Chair, will also accept the Orioles Heavy Hitter Award.

Mercy primary care physician Dr. Ernestine Wright discusses high blood pressure symptoms in women.